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Implication for health policy/practice/research/medical education:
Due to kidneys’ role in metabolism and excretion of toxic waste, they are subjects to drug toxicity.
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Chronic diseases affect the quality of life and self-care (1). Cancer or malignant tumor refers to clonal growth of tissue cells which are capable 
of invading and metastasizing to other parts of body (2-
5). Chemotherapy is one of the most effective treatment 
modalities that usually is used along with the surgery 
and radiation therapy for cancer treatment. Systemic 
chemotherapies are cytotoxic or cytostatic agent which 
interfere with function and repair of malignant cells and 
leading to cell dysfunction and death. In metastatic setting 
it is usually necessary to continue and repeat chemotherapy 
courses for long-term to prevent tumor progression. 
Chemotherapy drugs are classified based on their function, 
chemical structure and their correlation with other drugs 
(2,3,6).
With advancements in cancer therapy, 5-year survival 
rate has improved for these patients. As a result, a large 
proportion of cancer patients are exposed to chemotherapy 
and its short and long-term complication. Due to kidneys’ 
role in metabolism and excretion of toxic waste, they are 
subject to drug toxicity. Kidneys absorb 25% of cardiac 
output. In addition, renal tubules and proximal segments 
contain high capacity for reabsorption of medications 
via endocytosis or transporter proteins. High delivery 
and reabsorption rate leads to excessive intracellular 
concentration of various substances. Consequently, their 
massive metabolism results in potential toxic metabolites 
reactive oxygen species (ROS). Multiple chemotherapy 
agents are associated with various renal toxicity include 
tubulointerstitial injury, glomerular disease, electrolyte 
abnormality, hypertension and proteinuria  (7).
Cisplatin is one of the most commonly used 
chemotherapeutic agents, and it is also the most 
nephrotoxic agent. Cisplatin can decrease creatinine 
clearance and cause renal failure by the mechanism of 
tubulointerstitial injury. Cisplatin-induced nephrotoxicity 
is related to the dose and duration of treatment. Other 
platinum agents like carboplatin and oxaliplatin are less 
nephrotoxic. Therefore, their administration in patients 
with pretreatment renal dysfunction is much safer than 
cisplatin usage. 
Isosfamide and cyclophosphamide may cause 
hemorrhagic cystitis, renal toxicity, dysuria, urinary 
frequency. For hemorrhagic cystitis protection in patients 
who receive ifosfamide, mesna is recommended. 
Chemotherapy agents are most commonly associated 
with glomerular toxicity such as antiangiogenic agents, 
mitomycin and gemcitabine. Bevacizumab, a monoclonal 
antibody which is a vascular endothelial growth factor 
receptor (VEGFR) inhibitor, can cause proteinuria, 
urinary urgency. Bevacizumab and gemcitabine may lead 
to renal vascular injuries and thrombotic microangiopathy, 
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presenting with anemia, thrombocytopenia, high blood 
pressure, acute kidney injury, hematuria and proteinuria.
Cetuximab, another monoclonal antibody which is an 
epidermal growth factor receptor (EGFR) inhibitor, may 
lead to acute renal failure and crystal nephropathy (6-10).
Generally, chemotherapy does not cause kidney injury 
in all patients. However, the risk of this injury depends on 
many factors including:
I. Patient’s factors: age, baseline pretreatment renal 
function and other comorbidities.
II. Tumor factors: kidney involvement by tumor, pathologic 
subtype of tumor and urinary tract obstruction by tumor.
III. Treatment factors; chemotherapeutic agents, dose 
and duration of chemotherapy, single or multi-agent 
chemotherapy and concomitant treatment modalities 
like other systemic treatments or concurrent radiotherapy 
(6-10). Results of studies indicated that chemotherapy 
caused anemia and decreases glomerular filtration rate 
but it did not influence serum creatinine concentration 
and blood pressure at first stages (8,11). Besides putative 
therapeutic effects, chemotherapy drugs have many side 
effects including nephrotoxicity. Therefore, oncologists 
and consulting nephrologists must be aware of these side 
effects and their presenting signs and symptoms (6).
Conclusion
Chemotherapy drugs may improve cancer control and 
increase patient’s survival; but they have various side 
effects on all body systems including genitourinary system 
which require a treatment team to continuously take the 
preventive and protective measures to decrease the risk 
of side effects of these drugs and to manage them by a 
multidisciplinary approach. 
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